PRESS RELEASE published on 06/06/2024 at 13:00, 5 months 15 days ago Theralase(R) Successfully Destroys Lung Cancer Theralase® Technologies Inc. announces preclinical success with Rutherrin® compound in targeting Non-Small Cell Lung Cancer. Results show improved tumour destruction and slower progression Theralase Technologies Inc. Cancer Treatment Preclinical Study NSCLC Rutherrin Compound
BRIEF published on 06/04/2024 at 13:05, 5 months 17 days ago Technologie Theralase® efficace pour l'inactivation des virus Theralase Ruvidar Recherche Antivirale Heliyon Inactivation Des Virus
BRIEF published on 06/04/2024 at 13:05, 5 months 17 days ago Theralase® Technology Effective in Virus Inactivation Theralase Ruvidar Antiviral Research Virus Inactivation Heliyon
PRESS RELEASE published on 06/04/2024 at 13:00, 5 months 17 days ago Theralase(R) Technology Effective in Virus Inactivation Theralase Technologies Inc. announces successful inactivation of various viruses with lead compound RuvidarTM through peer-reviewed research. Potential for viral vaccine development highlighted Theralase Technologies Inc. RuvidarTM Peer-Reviewed Research Viral Inactivation Viral Vaccine Development
BRIEF published on 05/30/2024 at 13:05, 5 months 22 days ago Theralase publie ses états financiers du 1T2024 Résultats Financiers Traitement Du Cancer Theralase Étude II PDC
BRIEF published on 05/30/2024 at 13:05, 5 months 22 days ago Theralase Releases 1Q2024 Financial Statements Financial Results Cancer Treatment Theralase Study II PDCs
PRESS RELEASE published on 05/30/2024 at 13:00, 5 months 22 days ago Theralase(R) Release's 1Q2024 Financial Statements Theralase® releases unaudited interim consolidated 1Q2024 financial statements. Company to host conference call on June 6th, 2024. Study II update and Break Through Designation progress discussed Conference Call Financial Statements Break Through Designation Theralase Study II
BRIEF published on 04/24/2024 at 13:05, 6 months 27 days ago Theralase Technologies Inc. Completes $750,200 Funding Round Private Placement Pharmaceuticals Clinical Research Investment Theralase Technologies
BRIEF published on 04/24/2024 at 13:05, 6 months 27 days ago Theralase Technologies Inc. finalise une ronde de financement de 750 200 $ Investissement Placement Privé Médicaments Recherche Clinique Technologies Théralase
PRESS RELEASE published on 04/24/2024 at 13:00, 6 months 27 days ago Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering, raising $CAN 750,200 for research and development of cancer treatments Private Placement Theralase Technologies Inc. Research And Development Stock Offering Cancer Treatments
Published on 11/22/2024 at 00:00, 8 hours 20 minutes ago Gratomic Announces Company and Operational Update
Published on 11/21/2024 at 22:05, 10 hours 15 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 10 hours 30 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 12 hours 5 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 12 hours 10 minutes ago For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/22/2024 at 08:12, 8 minutes ago EQS-Adhoc: PVA TePla AG launches share buyback program to support strategic acquisitions and long-term compensation plans
Published on 11/22/2024 at 08:00, 20 minutes ago Addition of Mr Alain Nydegger as an Eligible Participant under the Group’s Matching Share Plan 2025-2028
Published on 11/22/2024 at 08:00, 20 minutes ago NOTICE OF EXTRAORDINARY GENERAL MEETING OF MULTITUDE P.L.C.
Published on 11/21/2024 at 06:58, 1 day 1 hour ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 1 hour ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 1 hour ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 1 day 12 hours ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 1 day 13 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
